FGF21 and Obesity: Given the liver-specific origin of circulating endogenous FGF21 and its ability to facilitate weight loss and reduced adiposity when used in various models of obesity, we envisioned utilizing this nonviral gene therapy strategy to deliver Hemagglutinin (HA)-tagged FGF21 to the liver in vivo.